Dewpoint Therapeutics has entered a strategic partnership with Evotec to progress the research and development of its oncology pipeline programmes comprising condensate modifying therapeutics (c-mods).

The c-mods will be advanced to the investigational new drug application (IND) stage leveraging INDiGO, a wholly integrated data-driven platform of Evotec.

Dewpoint's oncology pipeline programmes were discovered using its condensate biology and artificial intelligence technology platform to detect biomolecular condensate modulators. 

C-mods could offer new treatment options for complex ailments and targets that were previously undruggable.

Using Evotec’s expertise, the pre-clinical development candidates in Dewpoint’s pipeline will be de-risked and expedited to clinical trials in humans.

The deal will facilitate Dewpoint in expanding its capital efficiency while reducing risks. 

Dewpoint’s agreement is based on a risk-sharing approach under which Evotec is entitled to receive milestone and royalty payments contingent on the programmes' success.

Dewpoint Therapeutics CEO Ameet Nathwani stated: “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic. 

“Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high-quality INDs across the industry. 

“A strategic relationship of this nature significantly enhances our development capabilities which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec.”

In September 2023, Dewpoint and Chemify partnered to accelerate the discovery of molecules to treat cancer and neurodegeneration.